Gemcitabine + ACR-368
Phase 2Recruiting 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Head and Neck Squamous Cell Carcinoma
Conditions
Head and Neck Squamous Cell Carcinoma
Trial Timeline
Sep 25, 2024 → Aug 23, 2028
NCT ID
NCT06597565About Gemcitabine + ACR-368
Gemcitabine + ACR-368 is a phase 2 stage product being developed by Acrivon Therapeutics for Head and Neck Squamous Cell Carcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06597565. Target conditions include Head and Neck Squamous Cell Carcinoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06597565 | Phase 2 | Recruiting |
Competing Products
20 competing products in Head and Neck Squamous Cell Carcinoma